T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMSG
1201
DELISTED
Amsurg Corp
AMSG
| $14.2M | ﹤0.01% |
183,540
+161,134
| +719% | +$12.5M |
|
1202
Cal-Maine
CALM
$3.87B
| $14.2M | ﹤0.01% |
320,900
+9,050
| +3% | +$427K |
|
|
NTUS
1203
DELISTED
Natus Medical Inc
NTUS
| $14.2M | ﹤0.01% |
375,580
+10,450
| +3% | +$350K |
|
|
SAGE
1204
DELISTED
Sage Therapeutics
SAGE
| $14.2M | ﹤0.01% |
471,070
+89,545
| +23% | +$2.99M |
|
|
VAR
1205
DELISTED
Varian Medical Systems, Inc.
VAR
| $14.2M | ﹤0.01% |
196,545
+1,232
| +0.6% | +$89.3K |
|
1206
Under Armour
UAA
$2.3B
| $14.1M | ﹤0.01% |
352,580
-349,586
| -50% | -$14M |
|
1207
Ziff Davis
ZD
$1.92B
| $14.1M | ﹤0.01% |
256,320
+5,666
| +2% | +$315K |
|
1208
Unum
UNM
$14.7B
| $14M | ﹤0.01% |
441,338
-7,000
| -2% | -$237K |
|
1209
Darden Restaurants
DRI
$25.4B
| $14M | ﹤0.01% |
221,452
+1,220
| +0.6% | +$79.8K |
|
|
IVAC
1210
DELISTED
Intevac Inc
IVAC
| $14M | ﹤0.01% |
2,468,410
-161,790
| -6% | -$801K |
|
|
POLY
1211
DELISTED
Plantronics, Inc.
POLY
| $14M | ﹤0.01% |
318,470
+25,500
| +9% | +$1.06M |
|
1212
Weyco Group
WEYS
$437M
| $14M | ﹤0.01% |
503,688
-25,452
| -5% | -$699K |
|
|
YELL
1213
DELISTED
Yellow Corporation Common Stock
YELL
| $13.8M | ﹤0.01% |
1,570,360
+227,400
| +17% | +$2.03M |
|
|
ACAT
1214
DELISTED
Arctic Cat Inc
ACAT
| $13.7M | ﹤0.01% |
807,645
+119,540
| +17% | +$1.89M |
|
1215
Aspen Aerogels
ASPN
$504M
| $13.6M | ﹤0.01% |
2,743,740
-3,240
| -0.1% | -$14.2K |
|
1216
Lantheus
LNTH
$6.59B
| $13.6M | ﹤0.01% |
3,698,171
+1,800
| +0% | +$4.14K |
|
1217
Ingevity
NGVT
$2.59B
| $13.6M | ﹤0.01% |
+398,676
| New | +$12.4M |
|
|
ONC
1218
BeOne Medicines Ltd
ONC
$40.3B
| $13.5M | ﹤0.01% |
454,400
+1,700
| +0.4% | +$49.9K |
|
|
SYNH
1219
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $13.5M | ﹤0.01% |
353,770
+2,695
| +0.8% | +$118K |
|
1220
Nasdaq
NDAQ
$54.6B
| $13.5M | ﹤0.01% |
624,831
-1,659
| -0.3% | -$35.5K |
|
1221
Huntington Bancshares
HBAN
$35.9B
| $13.4M | ﹤0.01% |
1,502,555
+130,600
| +10% | +$1.28M |
|
1222
NVR
NVR
$17B
| $13.4M | ﹤0.01% |
7,536
+6,024
| +398% | +$10.3M |
|
1223
Constellium
CSTM
$3.95B
| $13.3M | ﹤0.01% |
2,834,091
-717,640
| -20% | -$3.69M |
|
1224
Ardelyx
ARDX
$1.01B
| $13.1M | ﹤0.01% |
1,504,315
-3,800
| -0.3% | -$31K |
|
1225
Helmerich & Payne
HP
$4.3B
| $13.1M | ﹤0.01% |
195,540
-5,460
| -3% | -$337K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.